October 5, 2020
FOR IMMEDIATE RELEASE
October 5, 2020
WASHINGTON, DC—At the 2020 LMG Life Sciences Awards virtual ceremony, Finnegan received the awards for “Patent Strategy Firm of the Year” and “Patent Impact Case of the Year.”
The “Patent Impact Case of the Year” award reflects the firm’s appellate victory in Kaken Pharmaceutical Co., Ltd.; Bausch Health Care v. Andrei Iancu. At the U.S. Court of Appeals for the Federal Circuit, on behalf of clients Kaken Pharmaceuticals and Bausch Health, Finnegan obtained a decision reviving a key patent covering the Jublia®pharmaceutical product directed to methods of using efinaconazole to treat onychomycosis. In the case on appeal from an inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB), Finnegan argued that the final written decision finding the patent obvious and therefore unpatentable was based on an erroneous claim construction ruling. The Federal Circuit agreed and issued a precedential opinion overturning the PTAB’s claim construction of a key term in the patent, reversing the PTAB’s finding of obviousness that led to the finding of unpatentability, and remanding the case back to the Board. The patent at issue, which is being asserted in multiple concurrent district court litigations, provides patent protection for Jublia®until 2026. Jublia®has achieved more than $1B in sales since launch.
LMG’s Patent Strategy Firm of the Year award recognizes Finnegan’s strength in working with innovators dedicated to creating life-saving and life-improving products, proving first-hand how deliberate and holistic IP asset protection makes the difference, particularly when it comes to enforcing rights to keep competitors at bay or defending against infringement allegations.
In addition to receiving two awards, the firm once again received top honors in the LMG Life Sciences rankings. Finnegan ranked as “highly recommended” in the intellectual property categories of Patent Prosecution, Patent Strategy & Management, General Patent Litigation, and Hatch-Waxman Patent Litigation (Branded). Finnegan’s Life Sciences practice includes more than 250 attorneys and professionals dedicated to serving our clients’ intellectual property needs in the biologics, biotechnology, branded Hatch-Waxman (ANDA), digital health, medical device and diagnostics, and pharmaceutical spaces. The following attorneys were ranked as 2020 LMG Life Sciences Stars:
Michele C. Bosch - General Patent Litigation, Patent Strategy & Management
Scott Burwell - General Patent Litigation, Hatch-Waxman Patent Litigation
Bryan C. Diner - Hatch-Waxman Patent Litigation, Patent Strategy & Management
Thomas L. Irving - Patent Prosecution, Patent Strategy & Management, General Patent Litigation
Michael Jakes - General Patent Litigation, Patent Strategy and Management
Howard W. Levine - General Patent Litigation, Hatch-Waxman Patent Litigation, Patent Strategy & Management
Charles E. Lipsey - General Patent Litigation, Hatch-Waxman Patent Litigation
John D. Livingstone - Hatch-Waxman Patent Litigation
Jill K. MacAlpine, Ph.D. - General Patent Litigation, Patent Strategy & Management, Hatch-Waxman Patent Litigation, Patent Prosecution
Leslie A. McDonell - Patent Prosecution, Patent Strategy & Management, General Patent Litigation
James B. Monroe - General Patent Litigation
William B. Raich, Ph.D. - General Patent Litigation
Barbara R. Rudolph Ph.D. - General Patent Litigation, Hatch-Waxman Patent Litigation
Contacts
Anand K. Sharma, Managing Partner
anand.sharma@finnegan.com
Mark D. Sweet, Chair
mark.sweet@finnegan.com
About Finnegan
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices all aspects of patent, trademark, and copyright, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to advertising, trade secret law, European patents and trade marks, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. Follow us on LinkedIn and Twitter.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Award/Ranking
Managing IP EMEA Awards 2024: Finnegan Shortlisted for Global Firm of the Year Award
February 19, 2024
Press Release
February 13, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.